专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20130244968A1 Uracyl Spirooxetane Nucleoside Phosphoramidates 有权
标题翻译：尿嘧啶螺吡啶核苷磷酰胺
公开(公告)号：US20130244968A1
公开(公告)日：2013-09-19
申请号：US13884852
申请日：2011-11-10
申请人： Tim Hugo Maria Jonckers , Pierre Jean-Marie Bernard Raboisson , Koen Vandyck , Steven Maurice Paula Van Hoof , Lili Hu , Abdellah Tahri
发明人： Tim Hugo Maria Jonckers , Pierre Jean-Marie Bernard Raboisson , Koen Vandyck , Steven Maurice Paula Van Hoof , Lili Hu , Abdellah Tahri
IPC分类号： C07H19/10
CPC分类号： C07H19/10 , A61K9/2068 , A61K9/284 , A61K9/2866 , C07H19/06
摘要： This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).
摘要翻译：本发明涉及用于治疗感染丙型肝炎病毒（HCV）的患者的立体化学纯的尿嘧啶螺吡啶核苷氨基磷酸酯。

72. 发明申请

US20130123244A1 Hetero-Bicyclic Derivatives as HCV Inhibitors 有权
标题翻译：异环双环衍生物作为HCV抑制剂
公开(公告)号：US20130123244A1
公开(公告)日：2013-05-16
申请号：US13812388
申请日：2011-07-26
申请人： Koen Vandyck , Wim Gaston Verschueren , Pierre Jean-Marie Bernard Raboisson
发明人： Koen Vandyck , Wim Gaston Verschueren , Pierre Jean-Marie Bernard Raboisson
IPC分类号： A61K31/549 , A61K31/4709 , A61K45/06 , A61K31/4375 , C07D403/14 , A61K31/517 , C07D417/14 , C07D471/04 , C07D401/14 , A61K31/4725
CPC分类号： A61K31/549 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K45/06 , C07D401/14 , C07D403/14 , C07D417/14 , C07D471/04 , C07D491/10
摘要： Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R′ have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
摘要翻译：式I的HCV复制抑制剂包括立体化学异构形式，以及其盐，水合物，溶剂化物，其中R和R'具有如本文所定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物及其在HCV治疗中单独或与其它HCV抑制剂组合的用途。

73. 发明授权

US08357687B2 Macrocyclic indole derivatives useful as hepatitis C virus inhibitors 有权
标题翻译：用作丙型肝炎病毒抑制剂的大环吲哚衍生物
公开(公告)号：US08357687B2
公开(公告)日：2013-01-22
申请号：US13058990
申请日：2009-08-14
申请人： David Craig Mc Gowan , Sandrine Marie Helene Vendeville , Pierre Jean-Marie Bernard Raboisson , Abdellah Tahri
发明人： David Craig Mc Gowan , Sandrine Marie Helene Vendeville , Pierre Jean-Marie Bernard Raboisson , Abdellah Tahri
IPC分类号： C07D515/08 , A61K31/407
CPC分类号： C07D515/08
摘要： Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Y, R1, R2, R4 and n have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
摘要翻译：包含立体化学异构体形式的式（I）的HCV复制抑制剂及其盐，水合物，溶剂化物，其中Y，R1，R2，R4和n具有权利要求中限定的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物及其在HCV治疗中的用途。

74. 发明授权

US08349869B2 Macrocylic inhibitors of hepatitis C virus 有权
标题翻译：丙型肝炎病毒的大肠杆菌抑制剂
公开(公告)号：US08349869B2
公开(公告)日：2013-01-08
申请号：US13412997
申请日：2012-03-06
申请人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Lili Hu , Abdellah Tahri , Dominique Louis Nestor Ghislain Surleraux , Karl Magnus Nilsson , Bengt Bertil Samuelsson , Åsa Annica Kristina Rosenquist , Vladimir Ivanov , Mikael Pelcman , Anna Karin Gertrud Linea Belfrage , Per-Ola Mikael Johansson , Sandrine Marie Helene Vendeville
发明人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Lili Hu , Abdellah Tahri , Dominique Louis Nestor Ghislain Surleraux , Karl Magnus Nilsson , Bengt Bertil Samuelsson , Åsa Annica Kristina Rosenquist , Vladimir Ivanov , Mikael Pelcman , Anna Karin Gertrud Linea Belfrage , Per-Ola Mikael Johansson , Sandrine Marie Helene Vendeville
IPC分类号： C07D487/04 , A61K31/33 , A61P31/14
CPC分类号： C07D487/04 , A61K31/427 , A61K31/4709 , A61K31/7056 , A61K38/05 , A61K38/212 , A61K45/06 , A61K47/60 , C07D245/04 , C07D277/56 , C07D401/14 , C07D417/04 , C07D417/14 , C07K5/06139 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393
摘要： Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要翻译：式（I）的HCV复制抑制剂和N-氧化物，盐和立体异构体，其中每个虚线表示任选的双键; X为N，CH，X为双键，C为C; R1是-OR7，-NH-SO2R8; R2是氢，并且其中X是C或CH，R2也可以是C1-6烷基; R 3是氢，C 1-6烷基，C 1-6烷氧基C 1-6烷基，C 3-7环烷基; R4是芳基或Het; n为3,4,5或6; R 5为卤素，C 1-6烷基，羟基，C 1-6烷氧基，苯基或Het; R6是C1-6烷氧基或二甲基氨基; R7是氢; 芳基; Het; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或与Het取代的C 1-6烷基; R8是芳基; Het; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或与Het取代的C 1-6烷基; 芳基是任选被一个，两个或三个取代基取代的苯基; Het是含有1至4个选自氮，氧和硫的杂原子并且任选地被一个，两个或三个取代基取代的5或6元饱和，部分不饱和或完全不饱和的杂环。含有化合物（I）的药物组合物和制备化合物（I）的方法。还提供了式（I）的HCV抑制剂与利托那韦的生物可利用组合。

75. 发明申请

US20120171157A1 Macrocyclic Inhibitors Of Hepatitis C Virus 有权
标题翻译：丙型肝炎病毒的大环抑制剂
公开(公告)号：US20120171157A1
公开(公告)日：2012-07-05
申请号：US13412997
申请日：2012-03-06
申请人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Lili Hu , Abdellah Tahri , Dominique Louis Nestor Ghislain Surleraux , Karl Magnus Nilsson , Bengt Bertril Samuelsson , Asa Annica Kristina Rosenquist , Vladimir Ivanov , Michael Pelcman , Anna Karin Gertrud Linnea Belfrage , Per-Ola Mikael Johansson , Sandrine Marie Helene Vendeville
发明人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Lili Hu , Abdellah Tahri , Dominique Louis Nestor Ghislain Surleraux , Karl Magnus Nilsson , Bengt Bertril Samuelsson , Asa Annica Kristina Rosenquist , Vladimir Ivanov , Michael Pelcman , Anna Karin Gertrud Linnea Belfrage , Per-Ola Mikael Johansson , Sandrine Marie Helene Vendeville
IPC分类号： A61K31/4709 , A61K31/7056 , C07D487/04 , A61K38/21 , C07D417/14 , A61P31/14
CPC分类号： C07D487/04 , A61K31/427 , A61K31/4709 , A61K31/7056 , A61K38/05 , A61K38/212 , A61K45/06 , A61K47/60 , C07D245/04 , C07D277/56 , C07D401/14 , C07D417/04 , C07D417/14 , C07K5/06139 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/393
摘要： Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要翻译：式（I）的HCV复制抑制剂和N-氧化物，盐和立体异构体，其中每个虚线表示任选的双键; X为N，CH，X为双键，C为C; R1是-OR7，-NH-SO2R8; R2是氢，并且其中X是C或CH，R2也可以是C1-6烷基; R 3是氢，C 1-6烷基，C 1-6烷氧基C 1-6烷基，C 3-7环烷基; R4是芳基或Het; n为3,4,5或6; R 5为卤素，C 1-6烷基，羟基，C 1-6烷氧基，苯基或Het; R6是C1-6烷氧基或二甲基氨基; R7是氢; 芳基; Het; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或与Het取代的C 1-6烷基; R8是芳基; Het; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或与Het取代的C 1-6烷基; 芳基是任选被一个，两个或三个取代基取代的苯基; Het是含有1至4个选自氮，氧和硫的杂原子并且任选地被一个，两个或三个取代基取代的5或6元饱和，部分不饱和或完全不饱和的杂环。含有化合物（I）的药物组合物和制备化合物（I）的方法。还提供了式（I）的HCV抑制剂与利托那韦的生物可利用组合。

76. 发明申请

US20120034678A1 Diaryl Ethers 有权
标题翻译：二芳基醚
公开(公告)号：US20120034678A1
公开(公告)日：2012-02-09
申请号：US13265588
申请日：2010-04-23
申请人： Samuel Dominique Demin , David Mc Gowan , Stefaan Julien Last , Pierre Jean-Marie Bernard Raboisson
发明人： Samuel Dominique Demin , David Mc Gowan , Stefaan Julien Last , Pierre Jean-Marie Bernard Raboisson
IPC分类号： C12N7/06 , C07D263/32 , C07D401/14
CPC分类号： C07D403/14
摘要： Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formula I as HCV inhibitors.
摘要翻译：式I的化合物：包括其任何可能的立体异构体，或其药学上可接受的盐和/或溶剂合物，以及药物制剂和式I化合物作为HCV抑制剂的用途。

77. 发明申请

US20110092460A1 CYCLOPROPYL POLYMERASE INHIBITORS 有权
标题翻译：环丙基聚合酶抑制剂
公开(公告)号：US20110092460A1
公开(公告)日：2011-04-21
申请号：US12999263
申请日：2009-07-01
申请人： Tim Hugo Maria Jonckers , Pierre Jean-Marie Bernard Raboisson , Koen Vandyck
发明人： Tim Hugo Maria Jonckers , Pierre Jean-Marie Bernard Raboisson , Koen Vandyck
IPC分类号： A61K31/513 , C07D405/04 , A61K31/675 , A61P31/12 , A61P31/14
CPC分类号： C07H19/073
摘要： Compounds of formula I: wherein: R2 is hydrogen or C1-C4alkyl; R3 and R4 are hydrogen, —C(═O)R5, or —C(═O)CHR6—NH2; or R3 is hydrogen and R4 is a monophosphate-, diphosphate-, or triphosphate ester; or R3 is hydrogen, —C(═O)CHR5, or —C(═O)CHR6—NH2 and R4 is each R5 is hydrogen, C1-C6alkyl, or C3-C7cycloalkyl; R6 is hydrogen or C1-C6alkyl; R7 is optionally substituted phenyl; naphthyl; or indolyl; R8 and R8′ are hydrogen, C1-C6alkyl, benzyl; or R8 and R8′ combined form C3-C7cycloalkyl; R9 is C1-C6alkyl, benzyl, or optionally substituted phenyl; provided that R2, R3 and R4 are not all hydrogen; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical formulations with the compounds I; the use of compounds I, including the compounds of formula I wherein R2, R3 and R4 are all hydrogen, as HCV inhibitors.
摘要翻译：式I化合物：其中：R 2是氢或C 1 -C 4烷基; R3和R4是氢，-C（= O）R5或-C（= O）CHR6-NH2; 或R3是氢，R4是单磷酸酯，二磷酸酯或三磷酸酯; 或R 3为氢，-C（= O）CHR 5或-C（= O）CHR 6 -NH 2，且R 4各自为R 5为氢，C 1 -C 6烷基或C 3 -C 7环烷基; R6是氢或C1-C6烷基; R7是任选取代的苯基; 萘基; 或吲哚基; R8和R8'是氢，C1-C6烷基，苄基; 或R 8和R 8'组合形式的C 3 -C 7环烷基; R 9为C 1 -C 6烷基，苄基或任选取代的苯基; 条件是R2，R3和R4不都是氢; 或其药学上可接受的盐或溶剂化物; 具有化合物I的药物制剂; 使用化合物I，包括其中R2，R3和R4均为氢的式Ⅰ化合物作为HCV抑制剂。

78. 发明申请

US20100240698A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS 有权
标题翻译：丙型肝炎病毒大肠杆菌抑制剂
公开(公告)号：US20100240698A1
公开(公告)日：2010-09-23
申请号：US11995573
申请日：2006-07-28
申请人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Sandrine Marie Helene Vendeville , Lili Hu , Wim Van De Vreken , David Craig McGowan , Abdellah Tahri , Dominique Louis Nestor Ghislain Surleraux
发明人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Sandrine Marie Helene Vendeville , Lili Hu , Wim Van De Vreken , David Craig McGowan , Abdellah Tahri , Dominique Louis Nestor Ghislain Surleraux
IPC分类号： A61K31/427 , C07D487/04 , A61K31/4709 , A61K31/4725 , A61P31/12
CPC分类号： C07D487/04 , C07K5/06165
摘要： Inhibitors of HCV of formula al and the N-oxides, salts, and stereochemically isomeric forms thereof, wherein R1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 8 to 12 membered bicyclic heterocyclic ring system containing one nitrogen, and optionally one to three oxygen, sulfur or nitrogen, wherein said ring system may be optionally substituted; L is a direct bond, —O—, —O—C1-4alkanediyl-, —O—CO—, —O—C(═O)—NR5a— or —O—C(═O)—NR5a—C1-4alkanediyl-; R2 is hydrogen, —OR6, —C(═O)OR6, —C(═O)R7, —C(═O)NR5aR5b, —C(═O)NHR5c, —NR5aR5b, —NHR5c, —NHSOpNR5aR5b, —NR5aSOpR8, or —B(OR6)2; R3 and R4 are hydrogen or C1-6alkyl; or R3 and R4 taken together may form a C3-7cycloalkyl ring; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要翻译：式A1的HCV的抑制剂及其N-氧化物，盐和立体化学异构形式，其中R 1是芳基或饱和的部分不饱和或完全不饱和的5或6元单环或8至12元双环杂环体系，其含有一个氮和任选的一至三个氧，硫或氮，其中所述环系可以任选被取代; L是直接键，-O - ， - O-C 1-4烷二基 - ， - O-CO - ， - O-C（= O）-NR 5a - 或-O-C（= O）-NR 5a -C 1-4烷二基 - ; R2是氢，-OR6，-C（= O）OR6，-C（= O）R7，-C（= O）NR5aR5b，-C（= O）NHR5c，-NR5aR5b，-NHR5c，-NHSOpNR5aR5b，-NR5aSOpR8 ，或-B（OR 6）2; R3和R4是氢或C1-6烷基; 或者R 3和R 4一起形成C 3-7环烷基环; n为3,4,5或6; p为1或2; 芳基是苯基，萘基，茚满基或1,2,3,4-四氢萘基，其各自可以被任选地取代。Het是含有1至4个杂原子的5或6元饱和，部分不饱和或完全不饱和的杂环，各自独立地选择来自氮，氧和硫，任选地与苯环稠合，并且其中基团Het作为整体可以任选被取代; 含有化合物（I）的药物组合物和制备化合物（I）的方法。还提供了式（I）的HCV抑制剂与利托那韦的生物可利用组合。

79. 发明申请

US20100041728A1 HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES 有权
标题翻译： HCV抑制大环磷酰胺
公开(公告)号：US20100041728A1
公开(公告)日：2010-02-18
申请号：US12526085
申请日：2008-02-08
申请人： Dmitry Antonov , Susana Ayesa Alvarez , Anna Karin Gertrud Linnea Belfrage , Carl Erik Daniel Jönsson , David Craig Mc Gowan , Karl Magnus Nilsson , Pierre Jean-Marie Bernard Raboisson , Åsa Annica Kristina Rosenquist , Bengt Bertil Samuelsson
发明人： Dmitry Antonov , Susana Ayesa Alvarez , Anna Karin Gertrud Linnea Belfrage , Carl Erik Daniel Jönsson , David Craig Mc Gowan , Karl Magnus Nilsson , Pierre Jean-Marie Bernard Raboisson , Åsa Annica Kristina Rosenquist , Bengt Bertil Samuelsson
IPC分类号： A61K31/407 , C07D245/04 , A61K31/33 , A61P31/12
CPC分类号： C07D245/04 , C07D255/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D498/04 , C07D498/14
摘要： Compounds of the formula 1: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
摘要翻译：式1的化合物：包括其立体异构体或N-氧化物，药学上可接受的加成盐或其药学上可接受的加成溶剂合物; 用作HCV抑制剂; 制备这些化合物的方法以及包含这些化合物作为活性成分的药物组合物。

80. 发明申请

US20090105302A1 Macrocylic Inhibitors of Hepatitis C Virus 有权
标题翻译：丙型肝炎病毒的大胆抑制剂
公开(公告)号：US20090105302A1
公开(公告)日：2009-04-23
申请号：US11995827
申请日：2006-07-28
申请人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Carl Erik Daniel Jonsson , Karl Magnus Nilsson , Bengt Bertil Samuelsson , Asa Annica Kristina Rosenquist , Dmitry Antonov , Lourdes Salvador Oden , Susana Ayesa Alvarez , Bjorn Olof Classon
发明人： Kenneth Alan Simmen , Herman Augustinus De Kock , Pierre Jean-Marie Bernard Raboisson , Carl Erik Daniel Jonsson , Karl Magnus Nilsson , Bengt Bertil Samuelsson , Asa Annica Kristina Rosenquist , Dmitry Antonov , Lourdes Salvador Oden , Susana Ayesa Alvarez , Bjorn Olof Classon
IPC分类号： A61K31/427 , A61P31/14 , C07D401/12 , A61K31/4523 , A61K31/407 , C07D417/12 , A61K31/4155 , A61K31/395
CPC分类号： C07D401/12 , C07D225/04 , C07D245/04 , C07D403/12 , C07D413/12 , C07D417/12 , C07D487/04
摘要： Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR6, —NH—SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy-carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1-4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1-3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
摘要翻译：式（I）的HCV复制抑制剂及其N-氧化物，盐或立体异构体，其中每个虚线（由 - - - - 表示）表示任选的双键; X为N，CH，X为双键，C为C; R1是-OR6，-NH-SO2R7; R2是氢，并且其中X是C或CH，R2也可以是C1-6烷基; R 3是氢，C 1-6烷基，C 1-6烷氧基C 1-6烷基或C 3-7环烷基; n为3,4,5或6; R 4和R 5彼此独立地是氢，卤素，羟基，硝基，氰基，羧基，C 1-6烷基，C 1-6烷氧基，C 1-6烷氧基C 1-6烷基，C 1-6烷基羰基，C 1-6烷氧基羰基，氨基，叠氮基，巯基， C 1-6烷硫基，多卤代C 1-6烷基，芳基或Het; W是芳基或Het; R6是氢; 芳基; Het; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或与Het取代的C 1-6烷基; R7是芳基; Het; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基，芳基或与Het取代的C 1-6烷基; 芳基是苯基或萘基，各自任选被1-3个取代基取代; Het是含有1-4个杂原子的5或6元饱和的，部分不饱和的或完全不饱和的杂环，各自独立地选自N，O或S，并且任选被1-3个取代基取代; 含有化合物（I）的药物组合物和制备化合物（I）的方法。还提供了式（I）的HCV抑制剂与利托那韦的生物可利用组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式